N
19.37
0.28 (1.47%)
Previous Close | 19.09 |
Open | 18.98 |
Volume | 288,584 |
Avg. Volume (3M) | 929,901 |
Market Cap | 2,073,616,640 |
Price / Sales | 51.21 |
Price / Book | 5.39 |
52 Weeks Range |
Operating Margin (TTM) | -85.89% |
Diluted EPS (TTM) | -2.21 |
Quarterly Revenue Growth (YOY) | 889.80% |
Total Debt/Equity (MRQ) | 0.13% |
Current Ratio (MRQ) | 10.61 |
Operating Cash Flow (TTM) | -154.16 M |
Levered Free Cash Flow (TTM) | -108.73 M |
Return on Assets (TTM) | -29.27% |
Return on Equity (TTM) | -47.37% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | NewAmsterdam Pharma Company N.V | Bearish | Bullish |
AIStockmoo Score
0.5
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | 2.0 |
Technical Moving Averages | -2.5 |
Technical Oscillators | -0.5 |
Average | 0.50 |
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
Sector | Healthcare |
Industry | Biotechnology |
% Held by Insiders | 0.41% |
% Held by Institutions | 89.16% |
Ownership
Name | Date | Shares Held |
---|---|---|
Fcpm Iii Services B.V. | 30 Sep 2024 | 11,831,461 |
Medicxi Ventures Management (Jersey) Ltd | 31 Dec 2024 | 2,869,565 |
Polar Capital Holdings Plc | 30 Sep 2024 | 1,505,000 |
Siren, L.L.C. | 30 Sep 2024 | 920,564 |
52 Weeks Range | ||
Price Target Range | ||
High | 48.00 (HC Wainwright & Co., 147.81%) | Buy |
Median | 43.50 (124.57%) | |
Low | 36.00 (Needham, 85.85%) | Buy |
Average | 42.75 (120.70%) | |
Total | 4 Buy | |
Avg. Price @ Call | 22.19 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
RBC Capital | 28 Jan 2025 | 40.00 (106.50%) | Buy | 21.45 |
24 Jan 2025 | 40.00 (106.50%) | Buy | 23.60 | |
HC Wainwright & Co. | 14 Jan 2025 | 48.00 (147.81%) | Buy | 23.67 |
30 Dec 2024 | 48.00 (147.81%) | Buy | 25.60 | |
Scotiabank | 11 Dec 2024 | 47.00 (142.64%) | Buy | 25.57 |
Needham | 05 Dec 2024 | 36.00 (85.85%) | Buy | 18.07 |
21 Nov 2024 | 36.00 (85.85%) | Buy | 20.12 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |